2023-08-22 18:25:08 ET
More on Celldex
- Celldex Therapeutics: Promising Phase 1b Results For Barzolvolimab In CSU
- Celldex gains 12% on Phase 1 data for urticaria candidate
- Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
- Celldex posts early-stage data to support dose-dependent effect of urticaria therapy
- Celldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program
- Seeking Alpha’s Quant Rating on Celldex
- Earnings data for Celldex
For further details see:
Wells Fargo starts Celldex at underweight, cites over-optimism for hives drug